Mens, M. et al. Circulatory MicroRNAs as Potential Biomarkers for Stroke Risk. Stroke. 2021 FEB 10 . https://doi.org/10.1161/STROKEAHA.120.031543
Guerrero-Zotano, A., et al. Plk1 expression & efficacy of Palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03). Cancer Res February 15 2021 (81) (4 Supplement) PS2-01; DOI: 10.1158/1538-7445.SABCS20-PS2-01
Bustos, M. A., et al. Identification of cell-free microRNA signatures in pre-operative plasma from breast cancer patients. Cancer Res February 15 2021 (81) (4 Supplement) PS2-17; DOI: 10.1158/1538-7445.SABCS20-PS2-17
Garcia-Flores, M., et al. Isolation and Characterization of Urine Microvesicles from Prostate Cancer Patients: Different Approaches, Different Visions. Research Square 2021 FEB DOI 10.21203/rs.3.rs-183251/v1. Preprint
Sinnberg, T., et al. IgA autoantibodies target pulmonary surfactant in patients with severe COVID-19. medRxiv preprint doi: https://doi.org/10.1101/2021.02.02.21250940 this version posted Feb 5, 2020.
Wu., J. et al. Biological Age in Healthy Elderly Predicts Dementia in the Absence of a Brain Marker. Research Square. DEC 11.2020 DOI: https://doi.org/10.21203/rs.3.rs-119310/v1. Preprint
Song, Y., et al. Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood Journal 2020. NOV 5 136(S1):10-11.
Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.
Gaudio, E., et al. Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identificaton of Potential Biomarkers for Its Activity. Blood Journal 2020 NOV 6. 136 (S1);17
Jacobs, S. A., et al. Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3ca) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical Cancer Research 2020 NOV 17 DOI: 10.1158/1078-0432.CCR-20-1831
Hou, M. M., et al. 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC). Journal for Immunotherapy of Cancer 2020(8)S3. Pre-print
Page last updated February 25, 2021